https://www.selleckchem.com/
On multivariate analysis, ECOG-status (p=0.003), simultaneous chemotherapy (p=0.003), time from metastasis detection to SBRT-treatment (≥2months; p=0.021) and LC of the treated metastases (≥12months, p0.009) were significant predictors for OS. One- and two-year PFI were 30.5% and 14%. Acute toxicity was mild and rare (14.4% grade I, 2.3% grade II, 0.6% grade III). Chronic °III/IV toxicities occurred in 1.1%. Patient selection, time to treatment and sufficient doses are essential to achieve optimal outcome for SBRT with active motion compensation. Local
Like
Comment
Share
